Disease-modifying therapies and infectious risks in multiple sclerosis (Q38760860)

6 September 2017

title

Disease-modifying therapies and infectious risks in multiple sclerosis (English)

1 reference

6 September 2017

0 references

4

Hans-Peter Hartung

1 reference

6 September 2017

Alexander Winkelmann

1

1 reference

6 September 2017

Micha Loebermann

series ordinal

2

1 reference

6 September 2017

Emil C Reisinger

series ordinal

3

1 reference

6 September 2017

Uwe K Zettl

series ordinal

5

1 reference

6 September 2017

language of work or name

English

0 references

publication date

4 March 2016

1 reference

6 September 2017

published in

Nature Reviews Neurology

1 reference

6 September 2017

volume

12

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

217-233

1 reference

Pathology and disease mechanisms in different stages of multiple sclerosis

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Inflammatory cortical demyelination in early multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Pathological mechanisms in progressive multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Spinal cord pathology in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Immune-mediated CNS diseases: a review on nosological classification and clinical features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Treatment optimization in MS: Canadian MS Working Group updated recommendations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Oral treatment for multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Immune therapy of multiple sclerosis--future strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Safety profile of IBD therapeutics: infectious risks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Biologics in children's autoimmune disorders: efficacy and safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Opportunistic infections and other risks with newer multiple sclerosis therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Secondary immunodeficiencies, including HIV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Mechanisms of glucocorticoids in the control of neuroinflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis--an observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Infections associated with steroid use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Pharmacology of glucocorticoids in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Therapeutic plasma exchange: complications and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Nosocomial Neisseria meningitidis sepsis as a complication of plasmapheresis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Safety of plasmapheresis in the treatment of neurological disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Complications of double-filtration plasmapheresis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Complications of plasma exchange in neurological patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Transmission of HIV and AIDS by plasmapheresis for Guillain-Barré syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Type I interferon dysregulation and neurological disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Fingolimod is a potential novel therapy for multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Fingolimod treatment for multiple sclerosis patients What do we do with varicella?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

VZV encephalitis that developed in an immunized patient during fingolimod therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Persistence and pathogenesis of the neurotropic polyomavirus JC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

PML in a patient with lymphocytopenia treated with dimethyl fumarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

PML in a patient treated with fumaric acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Manufacturer's response to case reports of PML

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

More on PML in Patients Treated with Dimethyl Fumarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Overview of azathioprine treatment in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

PML: The Dark Side of Immunotherapy in Multiple Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Reassessing the risk of natalizumab-associated PML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alemtuzumab: the advantages and challenges of a novel therapy in MS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Consumption of raw or unpasteurized milk and milk products by pregnant women and children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Getting specific: monoclonal antibodies in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Immunological risk factors for infection after immunosuppressive and biologic therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

JC polyomavirus granule cell neuronopathy in a patient treated with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Daclizumab (anti-CD25) in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Vaccination against infection in patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Immune Surveillance of the CNS following Infection and Injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Neurological immune reconstitution inflammatory response: riding the tide of immune recovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Identification and characterization of mefloquine efficacy against JC virus in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

The human polyomavirus, JCV, uses serotonin receptors to infect cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Treatment of progressive multifocal leukoencephalopathy with interleukin 7.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Exogenous and endogenous glucocorticoids in rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Plasma exchange and intravenous immunoglobulins: Mechanism of action in immune-mediated neuropathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Interferons and viral infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Interferon beta augments suppressor cell function in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Interferon beta in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Mechanisms of action of interferon-beta in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

The 'Immunological-Synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-β

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

The structure and function of the S1P1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

The role of natural killer cells in multiple sclerosis and their therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Mechanism of action for leflunomide in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Teriflunomide and its mechanism of action in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Managing the risks of immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Tumefactive multiple sclerosis and hepatitis C virus 2a/2C infection: Dual benefit of long-term interferon beta-1a therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

IFN-beta impairs superoxide-dependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

In vivo effects of recombinant-interferon-beta1b treatment on polymorphonuclear cell and monocyte functions and on T-cell-mediated antibacterial activity in patients with relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Protection against progressive leishmaniasis by IFN-beta.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Azathioprine for multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Breathlessness, night sweats, and weight loss on natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Cavitary pulmonary disease in a patient treated with natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Herpes encephalitis during natalizumab treatment in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Does natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Natalizumab and HSV meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Report of Three Cases of Herpes Zoster During Treatment with Natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Ocular toxoplasmosis during natalizumab treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Two cases of opportunistic parasite infections in patients receiving alemtuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.21

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

31 March 2020

1 reference

12 December 2020

Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function

1 reference

12 December 2020

Case reports of PML in patients treated for psoriasis

1 reference

12 December 2020

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

1 reference

12 December 2020

Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response

1 reference

12 December 2020

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis

1 reference

12 December 2020

Mitoxantrone: a novel anthracycline derivative

1 reference

12 December 2020

Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

1 reference

12 December 2020

Azathioprine for multiple sclerosis

1 reference

12 December 2020

Plasma exchange morbidity in Guillain-Barré syndrome: results from the French prospective, randomized, multicenter study. The French Cooperative Group

1 reference

12 December 2020

Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis

1 reference

12 December 2020

Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?

1 reference

12 December 2020

Rituximab for relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial

1 reference

12 December 2020

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 reference

12 December 2020

A fresh look at glucocorticoids how to use an old ally more effectively

1 reference

12 December 2020

Mitoxantrone for multiple sclerosis

1 reference

12 December 2020

Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2016.21

1 reference

Dimensions Publication ID

6 September 2017

1042914273

0 references

1 reference